Cyteir

cyteir.com

Actively hiring

As featured in

Nasdaq

Overview

News

Salaries

Products

People

Growth

Offices

Financials

Overview

Cancer's Vulnerability is Our Strength. Cyteir is a clinical-stage oncology company that is focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters.

News

News seekingalpha.com 3 years ago

Cyteir: Although The Company Is Winding Down, The Lead Asset Had Promise Read more

Report

News nasdaq.com 3 years ago

Cyteir Therapeutics (CYT) Price Target Increased by 7.14% to 2.55 Read more

Report

News fiercebiotech.com 3 years ago

Cyteir lays off 70% of workforce after further narrowing cancer drug goals Read more

Report

Press release theglobeandmail.com 3 years ago

Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash Runway Read more

Report

Press release businesswire.com 4 years ago

Cyteir Therapeutics Presents Poster on the Identification of Mechanism of Action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium Read more

Report

News nasdaq.com 4 years ago

Is Cyteir Therapeutics (NASDAQ:CYT) In A Good Position To Invest In Growth? Read more

Report

News bizjournals.com 4 years ago

The Petri Dish: Cyteir puts a drug on pause, Alexion vet joins Watertown biotech Read more

Report

Press release businesswire.com 4 years ago

Cyteir Therapeutics Reports Second Quarter 2022 Financial Results and Operational Highlights Read more

Report

News bizjournals.com 5 years ago

Shares of cancer biotech Cyteir down after $133M IPO Read more

Report

Press release PRNewswire 5 years ago

Cyteir Therapeutics Secures $80 Million in Series C Financing to Advance Clinical Trials of Lead RAD51 Program

/PRNewswire/ -- Cyteir Therapeutics, a leader in the discovery and development of next-generation synthetic lethal therapies for cancer, today announced the...

Report

Show more news